{"name":"Istituto Giannina Gaslini","slug":"istituto-giannina-gaslini","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Clofarabine VP 16 ciclophospahamide","genericName":"Clofarabine VP 16 ciclophospahamide","slug":"clofarabine-vp-16-ciclophospahamide","indication":"Acute lymphoblastic leukemia","status":"phase_2"}]}],"pipeline":[{"name":"Clofarabine VP 16 ciclophospahamide","genericName":"Clofarabine VP 16 ciclophospahamide","slug":"clofarabine-vp-16-ciclophospahamide","phase":"phase_2","mechanism":"Clofarabine VP 16 and cyclophosphamide work by interfering with DNA synthesis and function, leading to cell death in rapidly dividing cancer cells.","indications":["Acute lymphoblastic leukemia"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi0wJBVV95cUxPOThxR3QxTzRlRnBZOVVuVUUxZ0NqeXhudThyVS1rV0xMREROZTJGOTl5QXVDNkpvZE1KVk96ajJUMkJid2hvSExmcUNZTkx1ODdvclFHWHJtY1hubUwxTkFOS2tHUHNmQ1RvNVkxbDlIdGNMZ3NGSFhIN1cwQ3dTV21aUFRWX1RpdHp3Smdndm90S0ptdTIwcGE2X2lmY1JhaEMwZFNESWdkNGxVSTVYVXJHdVduU2MtNGpxdm1hYkRfWjItS0lCWHlsNmhtdFpQdW9FU0NsWnFfVnp0QUc0VXF3V045VkVPSWtlbXVCT3Rwa3dRMTZwSWtfQXotclZxY1F3ZlFfNW1HNzEtMnlHM1dJMFVtLTdFeU9xV1BVVXgxcXNlZ01abXYtT2dpMDBBLXBUdnNUU1BVSkVDVXlCMlV4dTZKdUQtT3QzVHdJMkdmbzg?oc=5","date":"2026-01-23","type":"regulatory","source":"Barchart.com","summary":"Rheumatoid Arthritis Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Eli Lilly and Company, Philogen, I-Mab Biopharma, Teijin Pharma, Revolo - ","headline":"Rheumatoid Arthritis Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTE9ZWnF1Q0pBRlhUbjdhdnFFRDFFbHlWeTRTVzhPYzR1cV91S01jdE1Ka21mQnBkZXVqcDBRbHZFdFliYUg1c2M4bUxaN1A5dEZyV1pLc0lMaDA1TjJuODE1RE53?oc=5","date":"2025-08-07","type":"pipeline","source":"ACS Publications","summary":"Polydopamine Nanoparticles as a Potential Non-Pharmaceutical Antioxidant Tool against Mitochondrial Disorders - ACS Publications","headline":"Polydopamine Nanoparticles as a Potential Non-Pharmaceutical Antioxidant Tool against Mitochondrial Disorders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQaDVWTERTTnQ1UUxfUTFNQ3BGeGdPT0RQTm1vanBoSkRoeEphblF3SUxxREoycV9RanRmVGZHM0JjTmdqd2tlOTk2OTZ5LUNmNDBCWHRlY2F1d0VBQnFuUWxqd2JYX2JXMzJtVXNySHNJUENDMnJWNktJdy04WmJEYWRVbkpEa1htaWVpSWNGcw?oc=5","date":"2024-02-08","type":"pipeline","source":"Frontiers","summary":"Editorial: Novel Mechanisms of Epileptogenesis and Its Inspired Pharmaceutical Treatments for Epilepsy - Frontiers","headline":"Editorial: Novel Mechanisms of Epileptogenesis and Its Inspired Pharmaceutical Treatments for Epilepsy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxNSU9IUkRWMkJnWndsaFhNdEhTWlVDZklIVUYzWWNxTFl6dUFlSWg4TFNxcC1VWkFUZFYxdEFNX0xNYXU5Vk5Fd2JKaFoteEJvdGJXN0FMUENHY2o3NXdIcUY2MVJCa3JaNlNzMHRaTG02M3E3UkFnUEtZMkItU3RoR3hpUDUyajlMbEt2OHB5QXpOOTZ2SW5hSlF1WkZnaTN4M1JhOGh1QUJ2bXRQa1RyelR4SzlzTW1zWEprRFUzWHRGZXcza0E?oc=5","date":"2016-09-15","type":"pipeline","source":"openPR.com","summary":"Muckle-Wells Syndrome Market Will Reflect Significant Growth Prospects during 2013-2019 - openPR.com","headline":"Muckle-Wells Syndrome Market Will Reflect Significant Growth Prospects during 2013-2019","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}